![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Innovative to change its name to 9 Meters Biopharma. 9 Biopharma meters to focus on delivering novel approach including the first and only long-acting GLP-1 agonist receptor for Short Bowel Syndrome.
Lead Product(s): Larazotide Acetate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Peptide
Recipient: Innovate Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 30, 2020